This study supports the application of targeted molecular therapy in thyroid cancer as suggested in earlier studies, by demonstrating that targeting mutated BRAF leads to drastic, selective phenotype changes in thyroid cancer cells in culture [31,32]. Here, BRAF is linked to thyroid gland carcinoma.